Table 5.
Analysis of clinical factors affecting PFS of radiotherapy and chemotherapy in intermediate and advanced cervical squamous cell carcinoma.
| Clinical factors | Cases | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| group | <0.001 | <0.001 | |||
| Chemoradiotherapy sensitive group | 44 | ref | ref | ||
| Chemoradiotherapy resistance | 43 | 4.80 (2.26-10.20) | 6.10 (2.58-14.41) | ||
| ASPH | 0.0369 | 0.3326 | |||
| low | 39 | ref | ref | ||
| high | 48 | 2.12 (1.05-4.30) | 1.50 (0.66-3.39) | ||
| Age | 87 | 0.99 (0.95-1.03) | 0.536 | 0.97 (0.92-1.03) | 0.2989 |
| Stage | |||||
| IIb-IIIa | 26 | ref | ref | ||
| ≥IIIb | 61 | 1.65 (0.75-3.62) | 0.216 | 1.60 (0.63-4.04) | 0.3250 |
| Tumor diameter | |||||
| <=4cm | 36 | ref | ref | ||
| >4cm | 51 | 2.35 (1.14-4.87) | 0.0213 | 3.33 (1.31-8.45) | 0.0115 |
| hemoglobin | 87 | 1.00 (0.98-1.01) | 0.758 | 1.01 (0.99-1.03) | 0.2463 |
| NLR | 87 | 1.25 (1.05-1.50) | 0.0132 | 0.99 (0.78-1.27) | 0.9595 |
| PLR | 87 | 1.00 (1.00-1.01) | 0.186 | 1.00 (1.00-1.01) | 0.7840 |
| Lymph node metastasis | 0.0194 | 0.3037 | |||
| No | 52 | ref | ref | ||
| Yes | 35 | 2.18 (1.13-4.18) | 1.52 (0.69-3.37) | ||
| The total duration of radiotherapy (month) | |||||
| <=8 | 39 | ref | ref | ||
| > 8 | 48 | 2.04 (1.02-4.08) | 0.0433 | 2.54 (1.14-5.66) | 0.0231 |
| Number of concurrent chemotherapy courses (weeks) | 87 | 0.93 (0.78-1.12) | 0.453 | 0.80 (0.63-1.02) | 0.0667 |
| Adjuvant chemotherapy course (weeks) | 87 | 1.01 (0.81-1.25) | 0.956 | 0.99 (0.76-1.28) | 0.9193 |